MBX Biosciences, Inc. (MBX) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in MBX Biosciences (MBX) by buying shares or fractional shares at any major broker, or holding it inside a thematic biotech basket. MBX is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, so it has no product revenue yet and its value rests on clinical trial outcomes rather than current earnings. As of November 20, 2026 the shares sit near $50.67, up about 66% year to date and about 87% over a year, but roughly 26% below where they were three months earlier.

MBX stock price

As of 2026-11-20, MBX Biosciences, Inc. (MBX) last closed at $49.55, up 83.0% over the past year. Over the past 52 weeks it has traded between $26.92 and $70.70.

MBX last close
$49.55
1 day
-7.23%
1 month
-8.12%
1 year
+82.98%
52-week range
$26.92 to $70.70
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or MBX Biosciences, Inc.'s investor relations page. Walnut is informational, not investment advice.

MBX key stats

At $49.55 on November 20, 2026, MBX Biosciences, Inc. (MBX) has a market cap of $2.5B.

Market cap
$2.5B
Price to book
5.2
Beta
0.18

Market cap, P/E and yield are measured at the $49.55 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with MBX Biosciences, Inc. (MBX)?

The last two weeks for MBX Biosciences, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • MBX closed at $49.55 on November 20, 2026, down 11.4% over the past five trading days (from $55.94).
  • On November 9, 2026, MBX Biosciences, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 9, 2026, MBX Biosciences, Inc. filed an 8-K with the SEC reporting quarterly results and information shared with investors (Regulation FD) (Item 2.02, Item 7.01). Read the 8-K on sec.gov
  • On November 12, 2026, HC Wainwright & Co. started coverage at Buy, target $90.00.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does MBX Biosciences, Inc. (MBX) do?

MBX Biosciences, Inc. (Nasdaq: MBX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel precision peptide therapies for endocrine and metabolic disorders. Its lead candidate is canvuparatide (MBX 2109), a once-weekly parathyroid hormone peptide prodrug for chronic hypoparathyroidism, which completed its End-of-Phase 2 FDA meeting and dosed the first patient in its registrational Phase 3 oPTimize trial on August 27, 2026. The pipeline also includes an obesity portfolio led by MBX 4291 (a once-monthly candidate in Phase 1), plus two newly nominated development candidates, the amycretin prodrug MBX 5765 and the GLP-1/GIP/glucagon triple-agonist prodrug MBX 6180, and imapextide (MBX 1416) for post-bariatric hypoglycemia in Phase 2. The company was founded around a peptide-engineering platform and went public in September 2024.

As a clinical-stage company, MBX generates no commercial product revenue and runs at a net loss as it funds research and development. The third-quarter 2026 loss, reported November 9, was $62.4 million, or $1.29 per share, against a $0.84 consensus and $21.6 million a year earlier: R&D rose to $32.0 million on Phase 3 start-up and obesity trial costs, and G&A jumped to $34.3 million, including $20.8 million of stock-based compensation from modified awards for the company's former CEO. The investment picture is therefore driven by pipeline progress and cash rather than profits: MBX reported roughly $481.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026, up from $418.6 million in June after $97.6 million of net proceeds from at-the-market stock sales, which it still expects will fund operations into 2029, past several key catalysts. The Phase 3 oPTimize trial is expected to enroll about 160 adults, and unblinded data from the first 12-week cohort of MBX 4291 are on track for the fourth quarter of 2026. The stock has re-rated sharply since its IPO on positive Phase 2 data for canvuparatide, which competes with Ascendis Pharma's approved daily Yorvipath, and the shares climbed as high as about $72.64 before pulling back. As of November 20, 2026 the stock closed near $50.67, up roughly 66% year to date and about 87% over twelve months, but down about 26% over three months, for a market capitalization near $2.5 billion. HC Wainwright initiated coverage at Buy with a $90 target on November 12. That valuation embeds high expectations, making the shares sensitive to trial readouts, FDA decisions, and the eventual commercial reception of any approved therapy.

What's driving MBX Biosciences, Inc. (MBX)?

1. Canvuparatide in chronic hypoparathyroidism.

The lead program is once-weekly canvuparatide (MBX 2109) for chronic hypoparathyroidism, a rare condition with limited hormone-replacement options. MBX presented positive one-year open-label extension data from its Phase 2 trial at ENDO 2026, with 57% of patients maintaining responder status at one year, and dosed the first patient in the registrational Phase 3 oPTimize trial on August 27, 2026, keeping to its third-quarter timeline. A weekly dosing schedule is positioned as a convenience advantage over the daily regimen of the approved comparator. The randomized, double-blind, placebo-controlled study is expected to enroll about 160 adults; the company has not given a topline date.

2. Emerging obesity portfolio.

MBX is building an obesity pipeline aimed at once-monthly dosing, led by MBX 4291. Preliminary blinded Phase 1 data from the first multiple-ascending-dose cohort showed mean weight loss of 7% (range 0-16%) at eight weeks, and unblinded results from the first cohort of a 12-week dosing part (30 mg weekly for four weeks, then 120 mg and 180 mg monthly) remain on track for the fourth quarter of 2026. The company has nominated two more development candidates, the amycretin prodrug MBX 5765 and the GLP-1/GIP/glucagon triple-agonist prodrug MBX 6180, with preclinical pharmacokinetic data on MBX 6180 presented at ObesityWeek in November 2026 and IND-enabling studies under way for both. Obesity is a very large market, so any differentiated dosing profile could expand the company's addressable opportunity well beyond rare disease.

3. Imapextide and pipeline diversification.

Imapextide (MBX 1416) targets post-bariatric hypoglycemia and is in Phase 2 development, with a Phase 2a readout expected in 2026. Having multiple shots across hypoparathyroidism, obesity, and post-bariatric hypoglycemia spreads clinical risk across several distinct programs rather than concentrating it in a single asset.

4. Cash runway through key catalysts.

MBX reported approximately $481.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026, up from about $418.6 million at the end of June because of $97.6 million of net proceeds from at-the-market stock sales, and it still expects the balance to fund operations into 2029. That runway is designed to carry the company through the canvuparatide Phase 3 and multiple pipeline readouts, though spending is rising: third-quarter R&D expense was $32.0 million, up from $19.3 million a year earlier, and the ATM sales show the company is willing to issue stock to extend it.

What are the risks to MBX Biosciences, Inc. (MBX)?

As a pre-revenue clinical-stage biotech, MBX carries binary clinical and regulatory risk: a failed or delayed Phase 3 for canvuparatide, or a negative FDA decision, could sharply reduce the value of the stock. The company generates no product revenue and posts recurring net losses, so it depends on its cash balance and additional financings that dilute existing shareholders, as the $97.6 million of at-the-market stock sales through September 2026 already did. Competition is real, with Ascendis Pharma's approved Yorvipath already commercial in hypoparathyroidism and AstraZeneca advancing eneboparatide via its Amolyt acquisition, while the obesity field is dominated by well-funded incumbents like Novo Nordisk and Eli Lilly. The valuation near $2.5 billion embeds high expectations for assets that are still years from potential approval, leaving the shares volatile and sensitive to any setback. Losses are widening as the Phase 3 ramps: the second-quarter 2026 loss of $0.78 per share was wider than the $0.59 analysts expected, and the third-quarter loss of $1.29 per share was wider than the $0.84 expected, partly because of $20.8 million of stock compensation tied to the former CEO. The stock is down about 26% over three months, and the fourth-quarter MBX 4291 readout is a near-term event that could move it either way.

What is the MBX Biosciences, Inc. (MBX) forecast?

11 analysts publish price targets on MBX, averaging $95.09 as of November 2026, or +91.9% against the $49.55 share price on November 20, 2026. The published targets run from $80.00 to $150.00, a wide spread, and the ratings split 12 buy, 0 hold, 0 sell. Over the last six months there have been 4 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MBX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is MBX a buy or a sell?

We give no verdict on MBX Biosciences, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Canvuparatide in chronic hypoparathyroidism. The lead program is once-weekly canvuparatide (MBX 2109) for chronic hypoparathyroidism, a rare condition with limited hormone-replacement options. The most optimistic published target, $150.00, assumes this works close to its best case.

The case against. As a pre-revenue clinical-stage biotech, MBX carries binary clinical and regulatory risk: a failed or delayed Phase 3 for canvuparatide, or a negative FDA decision, could sharply reduce the value of the stock. The most pessimistic target, $80.00, is roughly what MBX is worth if this bites instead.

Read the full bull and bear case on MBX, including what would have to change to break either one. Walnut is not an investment adviser.

Has MBX Biosciences, Inc. (MBX) split its stock?

No. MBX Biosciences, Inc. (MBX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is MBX Biosciences, Inc. (MBX) valued?

Market cap, P/E and dividend yield at today's price are in the MBX key stats above. The business figures below come from MBX Biosciences, Inc.'s reported results as of November 2026 and change when it next reports.

  • Product Revenue (TTM): ~$0 (clinical-stage, pre-revenue)
  • Q3 2026 Net Loss: ~$62.4 million (EPS -$1.29 vs -$0.84 est.)
  • Net Income (TTM): ~-$145 million
  • Cash & Marketable Securities (Q3 2026): ~$482 million (runway into 2029)

As of November 2026: MBX has no commercial revenue and runs at a loss, so traditional earnings multiples do not apply. As of November 20, 2026 the shares trade near $50.67 against a 52-week range of roughly $26.00 to $72.64, and the market capitalization of about $2.5 billion is roughly 5.2 times its cash pile, which reflects investor expectations for canvuparatide and the obesity pipeline rather than current fundamentals. Analysts expect a fourth-quarter loss of about $0.93 per share and a 2027 loss of about $4.35 per share; the 11 analysts tracked by Yahoo Finance average a target near $95.

Who competes with MBX Biosciences, Inc. (MBX)?

Hypoparathyroidism therapies

The most direct comparison for canvuparatide. Ascendis Pharma markets the approved daily hormone-replacement therapy Yorvipath (TransCon PTH), and AstraZeneca is advancing eneboparatide after acquiring Amolyt Pharma. Entera Bio is a smaller player developing an oral parathyroid hormone candidate.

Obesity and metabolic drug developers

For its obesity portfolio, MBX competes with dominant incumbents Novo Nordisk and Eli Lilly, whose GLP-1 franchises define the market, as well as emerging challengers such as Amgen, Viking Therapeutics, and Structure Therapeutics working on next-generation obesity agents.

Clinical-stage endocrine and peptide biotechs

As a broader peer group, MBX sits among clinical-stage biotechs building peptide and endocrine pipelines that compete for investor capital and clinical talent, where valuations rise and fall on trial data rather than sales.

What stocks are similar to MBX Biosciences, Inc. (MBX)?

Other names that sit close to MBX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in MBX Biosciences, Inc. (MBX)

There are three common ways to get MBX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MBX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MBX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on MBX Biosciences, Inc. (MBX)

MBX Biosciences is a pre-revenue, clinical-stage peptide biotech whose stock is a bet on its lead hypoparathyroidism candidate (now in a registrational Phase 3 that dosed its first patient in August 2026) and obesity pipeline, funded by about $482 million of cash but exposed to binary trial and regulatory risk. Losses widened sharply in the third quarter, and the first 12-week obesity data are due before year-end.

More on MBX Biosciences, Inc. (MBX)

Whether MBX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MBX a buy or a sell?, and where the stock could go from here in the MBX stock forecast.

For income investors, whether MBX pays a dividend and how the payout looks is covered in does MBX pay a dividend? And to weigh MBX against a peer, read the full side-by-side comparisons: MBX vs ASND and MBX vs AZN.

Wondering how MBX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about MBX Biosciences, Inc.

Ask Walnut's AI anything about MBX and see how it fits what you own.

FAQ

What does MBX Biosciences do?

+

MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, including chronic hypoparathyroidism, obesity, and post-bariatric hypoglycemia. It has no approved products yet and is focused on advancing its pipeline through clinical trials.

Does MBX have any revenue or profit?

+

No. MBX is pre-revenue and runs at a net loss (about $62.4 million in the third quarter of 2026 and about $145 million over the trailing twelve months) because it is still in clinical development. Its value is tied to pipeline progress and cash rather than current earnings, which is typical for early-stage biotech.

What is canvuparatide?

+

Canvuparatide (MBX 2109) is MBX's lead candidate, a once-weekly parathyroid hormone peptide prodrug for chronic hypoparathyroidism. It showed positive one-year Phase 2 extension data and the first patient was dosed in the registrational Phase 3 oPTimize trial on August 27, 2026.

How much cash does MBX have?

+

MBX reported roughly $481.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026, including $97.6 million of net proceeds from at-the-market stock sales, and it expects that balance to fund operations into 2029. That runway is meant to carry it through its lead Phase 3 and several pipeline readouts.

Who are MBX's main competitors?

+

In hypoparathyroidism, the key comparators are Ascendis Pharma (approved Yorvipath) and AstraZeneca's eneboparatide (via Amolyt). In obesity, MBX would face incumbents Novo Nordisk and Eli Lilly, plus emerging developers like Viking Therapeutics and Structure Therapeutics.

When did MBX Biosciences go public?

+

MBX Biosciences completed its initial public offering in September 2024 on the Nasdaq under the ticker MBX. The IPO raised capital to fund its clinical programs, including advancing canvuparatide toward Phase 3.

Why is MBX stock considered high risk?

+

As a clinical-stage biotech, MBX faces binary trial and regulatory risk: a failed or delayed trial or a negative FDA decision could sharply cut its value. It also has no product revenue, depends on its cash balance and future financings, and trades at a valuation that embeds high expectations.

How did MBX Biosciences do in its latest quarter?

+

For the third quarter of 2026, reported November 9, MBX posted a net loss of $62.4 million, or $1.29 per share, wider than the $0.84 consensus and up from $21.6 million a year earlier. R&D rose to $32.0 million and G&A to $34.3 million, including $20.8 million of stock compensation tied to modified awards for its former CEO. Cash ended the quarter at about $481.6 million.

How has MBX stock performed in 2026?

+

MBX closed at about $50.67 on November 20, 2026, up roughly 66% year to date and about 87% over the past year, but down about 26% over three months from a 52-week high near $72.64. The 11 analysts Yahoo Finance tracks have an average target near $95; HC Wainwright initiated at Buy with a $90 target on November 12.

What is the next catalyst for MBX Biosciences?

+

The nearest is unblinded data from the first 12-week dosing cohort of its once-monthly obesity candidate MBX 4291, which the company says is on track for the fourth quarter of 2026. The canvuparatide Phase 3 oPTimize trial, which began dosing in August 2026 and plans to enroll about 160 adults, has no announced topline date yet.

How can I invest in MBX?

+

MBX trades on the Nasdaq, so you can buy shares or fractional shares through any major brokerage, or gain exposure indirectly through biotech or small-cap ETFs that hold it. Walnut is not an investment adviser, and clinical-stage biotech stocks can be highly volatile, so this is descriptive information rather than a recommendation.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with MBX Biosciences, Inc.'s investor relations page or your broker before making investment decisions.